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Summary Preliminary data from recent clinical radioimmunoscintigraphy studies indicate that 99mTc-labelled murine monoclonal antibodies
(MAbs) E48 and U36 have a similar ability to target squamous cell carcinoma of the head and neck (HNSCC) selectively. In the present study
we describe additional aspects of murine and chimeric MAb (mMAb and cMAb) E48 and U36, which might influence the selection of one MAb
for adjuvant radioimmunotherapy. To make direct comparison possible, ten patients received 11.2 ± 0.3 and 11.1 ± 0.2 mg (n = 5) or 51.1 ±
0.1 and 51.0 ± 0.4 mg (n= 5) of both mE48 IgG and mU36 IgG labelled with 1311 and 1251 simultaneously and underwent surgery 7-8 days after
injection. The mean uptake of iodine-labelled mE48 IgG and mU36 was highest in tumourtissue, 8.9 ± 8.9 and 8.2 ± 4.4 %ID kg-' respectively.
Tumour to non-tumour ratios for oral mucosa, skin, muscle, blood and bone marrow aspirate were 2.5, 5.5, 25.2, 4.7 and 4.0 respectively in
the case of mE48 IgG and 2.3, 4.1, 21.0, 5.8 and 5.8 respectively in the case of mU36 IgG. The distribution of mMAbs E48 and U36
throughout tumours that had been collected in previous studies was heterogeneous when administered at a dose of 1 or 12 mg, and
homogeneous when administered at a dose of 52 mg. Administration of mE48 IgG (1-52 mg) resulted in a human anti-mouse antibody
response in 12 out of 28 patients, while for mU36 IgG (1-52 mg), this figure was three out of 18 patients. cMAb E48 was shown to be highly
effective in mediating antibody-dependent cellular cytotoxicity in vitro, while cMAb U36 and mMAbs E48 and U36 were not effective at all.
Rationales are provided that give priority to the start of adjuvant radioimmunotherapy trials with 1'6Re-labelled cMAb U36 IgG in head and
neck cancer patients who are at high risk for the development of locoregional recurrences and distant metastases.
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During 1996 approximately 41 090 Americans will develop head
and neck cancer and 12 510 will die from it. Worldwide more than
500 000 new cases are projected annually, and the incidence is
rising. In head and neck cancer, squamous cell carcinoma accounts
for approximately 90% of all tumours (Parker et al, 1996). About
one-third of these patients present with early-stage (I and II) head
and neck squamous cell carcinoma (HNSCC), while two-thirds
present with advanced disease (stage III and IV) (Vernham and
Crowther, 1994). Although early-stage HNSCC can, in the great
majority ofcases, be cured with surgery or radiotherapy alone, the
local failure rate after surgery and/or radiotherapy in advanced
stages is more than 50%. Moreover, about 25% of these patients
develop distant metastases (Stupp et al, 1994).
Despite an increase in the locoregional control of HNSCC,
owing to improved surgery and radiotherapy, current therapy regi-
mens have failed to increase the 5-year survival rate in HNSCC
patients (Parker et al, 1996). Whereas fewer patients tend to die
from uncontrolled locoregional disease, more patients are exposed
to the risk ofdeveloping distant metastases. Therefore, an effective
systemic adjuvant therapy is needed. To date, there is no evidence
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that adjuvant chemotherapy has any survival benefit (Stell and
Rawson, 1990). Among the innovative approaches for improving
the therapy of cancer is the use ofmonoclonal antibodies (MAbs).
MAbs labelled with radionuclides offer the potential of highly
localized radiation treatment of cancer (Goldenberg, 1989).
Radioimmunotherapy (RIT) may be particularly suitable for the
treatment ofHNSCC owing to the intrinsic radiosensitivity ofthis
tumour type (Wessels et al, 1989).
For effective adjuvant RIT, it is a requirement that the MAb
shows ahigh and selective uptake as well as retention in all tumour
deposits, including tumour nodules, malignant cell clusters and
single tumour cells. When 1-emitters are used for RIT, it is not
necessary thatradiolabelled MAbs bind to each single cell within a
tumour because of the cross-fire effect. Despite this, heteroge-
neous distribution of a radioimmunoconjugate throughout the
tumour is unwanted in RIT because this can result in overkill in
certain tumour areas, while leaving other areas relatively unaf-
fected. When using chimerized, humanized or human MAbs in
RIT, it can be anticipated that antibody-dependent cellular cyto-
toxicity (ADCC) may be supportive to irradiation, especially in
eradicating single disseminated cells or small cell aggregates
(Riethmuller et al, 1995). For the most efficient mediation of
ADCC, these MAbs should preferably contain a human yl
constant region (Steplewski et al, 1988). Such MAbs may also be
less immunogenic than murine MAbs, which is of importance
when repeated administrations are needed for effective therapy
(Khazaeli et al, 1994).
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For use in adjuvant RIT of HNSCC, we produced a panel of
MAbs. Two of these MAbs, designated E48 and U36, are selec-
tively reactive with normal and malignant squamous and transi-
tional epithelia (Quak et al, 1990; Schrijvers et al, 1993). While
MAb E48 shows a homogeneous reactivity with 70% of HNSCC,
for MAb U36 this approaches 96% reactivity (De Bree et al,
1994a). The biodistribution of 99mTc-labelled mE48 IgG and
mU36 IgG has been evaluated by radioimmunoscintigraphy (RIS)
and by biopsy measurement (De Bree et al, 1994b, 1995a,b) in 24
and ten HNSCC patients respectively. Both MAbs were shown to
be highly capable of selective tumour targeting in HNSCC
patients, and the tumouruptake 2 days afterinjection was similarly
high, 30.6 + 20.1 %ID kg-' for mMAb E48 and 20.4 ± 12.4 %ID
kg-1 for mMAb U36 (De Bree et al, 1995a,b). Most recently,
chimeric (mouse/human) E48 IgGi and U36 IgG, have been
constructed (Brakenhoff et al, 1995).
Dataobtained from these studiesjustify the furtherdevelopment
of one of these MAbs for adjuvant RIT. In this paper, we evaluate
the potential ofthese MAbs for adjuvant therapy in a comparative
way. To eliminate interindividual variations, mMAbs E48 and U36
were now administered simultaneously. Moreover, we used iodine
labels to be able to assess the biodistribution of mMAbs at later
time points. We report on (1) the biodistribution ofsimultaneously
injected iodine-labelled mE48 IgG and mU36 IgG, 7-8 days after
injection; (2) the distribution of the mMAbs throughout the
tumour in relation to the administered MAb dose; (3) the immuno-
genicity of the mMAbs; and (4) the potential of the murine and
chimeric versions of the MAbs to mediate ADCC. Based on our
present and previous data, we come to a design for a first RIT trial
in head and neck cancer patients.
MATERIALS AND METHODS
Monoclonal antibodies
MAb E48 was derived from a mouse immunized with cells from a
metastasis ofa moderately differentiated squamous cell carcinoma
of the larynx. The antigen recognized by MAb E48 is a 16- to 22-
kDa glycosylphosphatidylinositol-anchored membrane protein
located on the outercell surface (Quak et al, 1990). The MAb E48-
defined antigen was expressed in 94% of the primary HNSCCs (n
= 196). In 70% ofthese tumours, the antigen was expressed by the
majority of the cells within these tumours. A similar reactivity
pattern was observed in 31 tumour-infiltrated lymph nodes from
neck dissection specimens (De Bree et al, 1994a). MAb reactivity
with normal tissues is restricted to normal stratified squamous
epithelium and urothelium ofthe bladder.
MAb U36 was derived after immunization of mice with viable
cells of the HNSCC cell line, UM-SCC-22B. The antigen recog-
nized by MAb U36 is a 200-kDa protein located at the outer cell
surface (Schrijvers et al, 1993). The MAb U36-defined antigen is
expressed by 99% of the primary HNSCCs (n = 196). In 96% of
these tumours, the antigen was expressed by the majority of cells
within these tumours. A similarreactivity pattern was observed in
31 lymph node metastases (De Bree et al, 1994a). MAb reactivity
with normal tissues is restricted to normal stratified squamous
epithelium and urothelium ofthe bladder.
Chimeric (mouse/human) MAbs E48 and U36 containing the
human yl constant region were constructed by recombinant DNA
technology as described previously (Brakenhoff et al, 1995).
cSF-25 is the chimeric form of MAb SF-25, which has been
developed and characterized by Takahashi et al (1988). The
antigen recognizedby MAb SF-25 is a 125-kDa proteinexpressed
by adenocarcinomas ofthe colon and among normal tissues in the
distal tubule ofthe kidney.
Biodistribution of iodine-labelled mE48 IgG and mU36
IgG simultaneously injected into ten HNSCC patients
The protocol was approved by the Dutch Health Council and by
the institutional review board of the Free University Hospital.
Informed consent was obtained from all patients. Ten patients with
HNSCC were injected with iodine-labelled mE48 IgG and mU36
IgG simultaneously. Before enrolment a biopsy of the primary
tumour had to show E48 IgG- and U36 IgG-positive immunoper-
oxidase staining with more than 75% of the tumour cells. The
primary tumour and the status of the neck lymph nodes were clas-
sified according to the TNM system of the International Union
Against Cancer, the UICC (Hermanek and Sobin, 1987).
All patients received 1.2 + 0.2 mg of mE48 IgG and 1.1 ± 0.3
mg of mU36 IgG radiolabelled with either 13'l (mean dose 75.8 ±
3.8 MBq) or 1251 (mean dose 3.2 ± 0.5 MBq) by intravenous injec-
tion in 5 min. Patient and tumour characteristics and injected MAb
dose are listed in Table 1. In five cases, mE48 IgG was labelled
with 1251 and mU36 IgG with 131I. In the otherfive cases mE48 IgG
and mU36 IgG were labelled with 13'I and 1251 respectively. Five
Table 1 Patient and tumour characteristics and injected MAb doses
Patient Age Sex Stages Primary tumour sitea E48 IgG dose (mg) U36 1gG dose (mg)
Labelled Unlabelled Labelled Unlabelled
1 59 M pT3N1 Oral cavity, lateral tongue 1.0 10.0 1.0 10.0
2 52 F pT3NO Oral cavity, floor of mouth 1.6 10.0 1.0 10.0 3 54 M pT3N2b Oral cavity, lateral tongue 1.5 10.0 1.0 10.0 4 41 M pT3N1 Oral cavity, lateral tongue 1.0 10.0 1.4 10.0 5 45 M pT3N2b Oropharynx, tonsil 1.0 10.0 1.3 10.0 6 50 M pT3N2b Oropharynx, posterior pharyngeal wall 1.0 50.0 1.3 50.0 7 65 M pT2N2b Oral cavity, lateral tongue 1.2 50.0 0.7 50.0 8 68 M pT3N1 Oral cavity, lateral tongue 1.0 50.0 1.5 50.0 9 50 M pT4N2b Oral cavity, retromolar area 1.3 50.0 1.0 50.0 10 65 M pT3N2c Oral cavity, floor of mouth 1.0 50.0 0.7 50.0
a All tumours are squamous cell carcinomas and are staged according to the TNM system of the IUCC.
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patients additionally received 10.0 mg, and five patients addition-
ally received 50.0 mg ofboth unlabelled mE48 IgG and unlabelled
mU36 IgG at the time of injection of the radiolabelled MAbs. To
prevent uptake of radioactive iodine in the thyroid gland, all
patients received Lugol's solution seven droplets three times a day
for 7 days starting 1 day preinjection. RIS was performed with a
large field of view gamma camera (Dual Head Genesys Imaging
system, ADAC Laboratories, Milpitas) equipped with high-energy
parallel-hole collimators and connected to a computer (Pegasys,
ADAC Laboratories, Malpitas) as described previously (De Bree
et al, 1995b). Planar anterior and posterior images ofthe head and
neck and whole-body images were obtained up to 8 days post
injection
Before and up to 7 days after administration of the radioim-
munoconjugates, urine and blood were obtained for analysis as
described previously (De Bree et al, 1994b). Vital signs were
recorded before and up to 3 h after injection.
Radiolabelling ofmE48 IgG andmU36 IgG
mE48 IgG and mU36 IgG were prepared, purified and radiola-
belled as described previously (De Bree et al, 1995a, b). The puri-
fied mE48 IgG was 1311 or 125I-labelled with a specific activity of
79.2 ± 25.7 MBq mg-' or 3.1 ± 0.4 MBq mg-' protein respectively.
For mU36 IgG these values were 64.8 ± 19.6 MBq mg-' and 3.5 +
0.4 MBq mg-' protein respectively. The mean 131I and 125I incorpo-
ration percentages were 98.5 ± 1.3% and 97.1 ± 2.2%, respec-
tively, as determined by chromatography on ITLC-SG strips
(Gelman Sciences, Ann Arbor, MI,USA) with 0.1 M citrate buffer,
pH 5.0. As determined by a modified Lineweaver-Burke plot, the
immunoreactive fractions of 1311- or 1251-labelled mE48 IgG and
mU36 IgG at infinite antigen excess always exceeded 68%. The
affinity constants were 1.2 x 1010 M-1 for mE48 IgG and 3.5 x 1010
M-1 for mU36 IgG as determined by Scatchard analysis.
Biodistribution ofMAbs 7-8 days afterinjection
Biopsies of the primary tumour and several other tissues were
taken from the surgical specimens of all patients. Blood, bone
marrow aspiration and bone marrow biopsy (containing bone and
bone marrow) were taken under general anaesthesia just before
surgery. All biopsies were weighed and the amounts of 125I and 13l1
were measured by differential counting methods in a well-counter
(1282 Compugamma, LKB Wallac, Turku, Finland) to compare
biodistribution of mE48 IgG and mU36 IgG. The effect of self-
absorption by volume effects was corrected by comparison of the
sample with a set of reference samples, prepared by diluting an
equal amount of the standard in different volumes of saline. All
data were corrected fordecay and converted to percentage injected
dose perkilogram (%IDkg-1) tissue. Ifin apatient several biopsies
ofone kind oftissue were taken, the mean uptake in this tissue was
calculated and used for further analysis. Tumour to non-tumour
ratios were calculated using matched uptake values of each
patient. After counting, all biopsies were analysed histopathologi-
cally to determine the presence or absence ofHNSCC.
Pharmacokinetics
Blood samples were obtained from the arm opposite to the injec-
tion site for the determination ofactivity up to 7-8 days p.i. Urine
was collected over the first 48 h. Aliquots of blood and urine
samples were measured for 13l1 and 125I activity in a well counter,
compared with an aliquot retained from the conjugate preparation
and corrected fordecay. Blood activity was expressed as %IDkg-'.
High-performance liquid chromatography (HPLC) analysis of the
serum samples revealed that more than 95% of the radioactivity
was bound to the MAb. The pharmacokinetics was analysed
modelling a time vs radioactivity curve for each infusion as
described previously (De Bree et al, 1995a,b). Excretion in the
urine was expressed as the percentage of the injected dose in this
period.
Bone marrowdosimetry
Blood and whole-body dataofboth the 125I- and '3II-labelled mE48
IgG and mU36 IgG were used to calculate the marrow dose. The
residence times of mMAb E48 and mMAb U36 in the blood and
whole body were derived from numerical integration ofthe blood
and urinary time activity curves. The blood and whole-body time
activity curves were extrapolated to infinity using the decay factor
between the last two measurement points. The activity in the
whole body was assumed to be homogeneously distributed. No
specific uptake in bone marrow was observed by RIS during the
first days after injection. Therefore, the red marrow-blood activity
ratio was assumed to be 0.3 (Siegel et al, 1990). The red marrow
dose was calculated according to MIRDDOSE2 (Watson and
Stabin, 1984). The red marrow dose was estimated from the
kinetic data and a 131I label.
Statisticalanalysis
The Student's t-testforpaired andunpaired data was used to deter-
mine the statistical significance of the difference between the
uptake of mE48 IgG and mU36 IgG. Statistical difference was
reached at P < 0.05.
Further characteristics of E48 IgG and U36 IgG
To obtain more information on the characteristics of E48 IgG and
U36 IgG, data from this and previous studies with radiolabelled
E48 IgG or U36 IgG alone were combined. The patient popula-
tions fromprevious studies have been describedbefore (De Bree et
al, 1994b, 1995a,b). In these studies, 19 patients received mE48
F(ab')2, nine patients received mE48 IgG, 15 patients received
mE48 F(ab')2 as well as mE48 IgG, and ten patients received
mU36 IgG.
Distribution ofthe MAbs throughout the tumour
Cryosections were made from tumour biopsies obtained from
patients included in previous studies (De Bree et al, 1995a,b).
These biopsies had been taken 2 days after injection of either
mE48 IgG or mU36 IgG. The in vivo distribution of the injected
MAb throughout the tumour was compared with the maximal
MAb binding on serial sections. In short, 5-,um-thick sections of
frozen tissue biopsies were cut on a cryostat microtome and
mounted on poly-L-lysine-coated glass slides, dried, fixed in 2%
paraformaldehyde in phosphate-buffered saline (PBS) for 10 min
and dried again.
To assess the distribution of the injected MAb throughout the
tumour, the specimens were incubated for 30 min with rabbit anti-
mouse IgG (Dako, Glostrup, Denmark) diluted 1:25 in PBS/1%
normal rabbitserum/l% bovine serumalbumin (BSA). The sections
were washed three times with PBS and incubated for 1 h with alka-
line phosphatase monoclonal anti-alkaline phosphatase (APAAP,
Dako) diluted in PBS/1% BSA. The sections were washed again
with PBS/1% BSA,rinsed with0.1 M Tris,pH 8.2, and incubated in
the dark for 20 min with naphthol AS-TR-phosphate/fast red violet
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LB substrate (both from Sigma). The substrate was prepared as
follows: 6 mg naphthol AS-TR-phosphate dissolved in 250 ml of
dimethylformamide was added to 10 ml of 0.1 M Tris-HCl, pH 8.2,
containing 10,ul of 1 M levamisole. Immediately before this prepa-
ration was used, 10 mg offastred violet LB was added and the solu-
tion was filtered. Sections were washed for 1 min with running
tap-water and counterstained with haematoxylin for 45 s, dehy-
drated and covered with Kaiser's glycerol gelatin (Merck,
Amsterdam, The Netherlands).
Maximum MAb binding was assessed in the same way, except
that the specimens were incubated with undiluted hybridoma
culture supernatantcontaining the MAb corresponding to the MAb
used forinjection. Isotype-matched control MAbs and PBS served
as negative controls.
Human anti-mouse antibody (HAMA) responses
Patients In the present study, all data on HAMA responses of
patients included in the present and previous RIS studies (De Bree
etal, 1994b, 1995a,b), and injected with mE48 F(ab')2, mE48 IgG,
mU36IgG or combinations thereof, are presented. The presence of
human anti-mouse antibodies was tested in patients' sera before
and 4-8 weeks after injection of radiolabelled mE48 F(ab')2
(group 1, n = 16); mE48 IgG (group 2, n = 5); mE48 F(ab')2 plus
mE48 IgG (group 3, n = 13); mU36 IgG (group 4, n = 8); or mE48
IgGplus mU36 IgG (group 5, n = 10).
Fourteen patients in group 1 received 1 mg and two patients
received 11 mg of mE48 F(ab')2. The five patients of group 2
received 1 mg ofmE48IgG. Tenpatients in group 3 received 2 mg,
onepatient 12 mg and twopatients 52 mg ofmE48 IgG simultane-
ously with 1 mg ofmE48F(ab')2. Fourpatients in group 4 received
2 mg, two patients 12 mg and two patients 52 mg of mU36 IgG.
Five patients in group 5 simultaneously received 11 mg of mE48
IgG and 11 mg of mU36 IgG, while five patients simultaneously
received 51 mg of mE48 IgG and 51 mg ofmU36 IgG.
AssayHAMA responses were analysed with an assay,essentially
as describedpreviously (Buist et al, 1995a); briefly, murine MAbs
E48 (Fab')2, E48 IgG or U36 IgG (20 pg per well) were bound to
the wells of a microtitre plate, coated with goat polyclonal anti-
mouse IgG antibodies (Dako Z0420). Patients' sera were predi-
luted stepwise: 1:50, 1:200, 1:800 and 1:3200, and incubated at
100 MI per well in duplicate. As controls, a negative serum was
diluted 1:50 and a positive serum 1:1500. Any human IgG bound
was detected with horse-radish peroxidase-labelled rabbit anti-
human IgG (Dako P0212) and o-phenylenediamine as substrate.
Reactions were performed at room temperature, until the
absorbance of the control serum wells reached a value of approxi-
mately 1.0. The reaction was stopped by adding 50jM of 4N
sulphuric acid, and the extinction was measured at 490 nm in a
plate reader. The reciprocal serum dilution yielding an absorbance
reading of 1.0 is called the HAMA titre and is calculated from the
formula: HAMA titre = (A- I)x(Z-Y)I(A-B) + Y, where Y is the
serum dilution corresponding to the nearest optical density (A)
above 1.0 and Z is the serum dilution corresponding to the nearest
optical density (B) below 1.0. A HAMA titre of 2500 was arbi-
trarily considered to be positive. HAMA titres provided are the
mean of duplicate or triplicate analyses. Standard errors of the
mean have been omitted, as they were less than 8%. Sera obtained
from patients injected with a combination of mE48 F(ab')2 and
IgG were analysed with a mE48 F(ab')2- and a mE48 IgG-related
HAMA assay, which means that mE48 F(ab')2 and mE48 IgG was
used as catcher respectively. Analagously, mE48 IgG- and mU36
IgG-related HAMA assays were used for the analysis of sera
obtained from patients who had received mE48 IgG and mU36
IgG simultaneously.
Antibody-dependent cellular cytotoxicity
UM-SCC-22A cells served as target cells, and peripheral blood
mononuclear cells (PBMCs) were obtained from healthy volun-
teers as effector cells in ADCC assays. PBMCs were obtained as
described previously (Brakenhoff et al, 1995)
Target cells were trypsinized with 0.05% trypsin, 0.02% EDTA
in PBS (Gibco Life Technologies), washed with tissue culture
medium and resuspended in tissue culture medium at a concentra-
tion of 105 cells ml-'. For ADCC assays with mMAb E48 or cMAb
E48, 2.5 [tCi of sodium [51Cr]chromate was immediately added
together with 5 x 103 cells (50 [LI) in the wells of 96-well U-
bottomed plates (Greiner, Westmalle, Belgium). Since the reac-
tivity of MAb U36 with UM-SCC-22A cells is lost upon
trypsinization of these cells, the ADCC assay was slightly modi-
fied for testing the ADCC-mediating activity of mMAb U36 and
cMAb U36. In this case, UM-SCC-22A cells were incubated for
48 h in 96-well U-bottomed plates before 2.5 [tCi of 51Cr was
added, thus allowing total recovery ofU36 antigen expression and
MAb U36 binding [as assessed by enzyme-linked immunosorbent
assay (ELISA) methods]. At the moment of 51Cr addition, each
well contained 5 x 103 target cells.
After incubation of the cells for 16 h with 5'Cr in 5% carbon
dioxide at 37°C, the cells were washed three times with
Dulbecco's modified Eagle medium (DMEM)/5% FCS, effector
cells were added at different effector-target (E:T) ratios ranging
from 6.25:1 to 100:1 and MAbs were added to a final concentra-
tion of 10 pg ml-'. Plates were centrifuged at 65 x g for 30 s and
incubated in 5% carbon dioxide at 37°C for 5 h after which
medium was harvested from each well. All assays were performed
in triplicate. Radioactivity was counted in a gamma-counter (1282
CompuGamma). Maximum radionuclide release was determined
by incubation of target cells in the presence of 5% Triton X-100.
Natural killer (NK) cell release (antibody-independent lysis) was
measured by incubation of target-effector cells in the presence of
the murine IgG, control anti-myosin MAb Myoscint (Centocor
Inc.), which does not bind to the target cells. The percentage of
specific lysis was calculated as the [(experimental release-back-
ground release)/(Triton release-background release)] x 100.
Background release is defined as the release in the absence of
specific antibody (= spontaneous release + NK release). Standard
deviations were typically 0-8%.
RESULTS
Biodistribution of iodine-labelled mE48 and mU36 IgG
simultaneously injected into ten HNSCC patients
No adverse reactions were observed that could be related to the
simultaneous injection of iodine-labelled mMAb E48 and mMAb
U36. No significant changes were noted in blood and urine para-
meters except for TSH values. In three patients, TSH was found
transiently below normal after injection. In one of these patients,
TSH was already at the lower limit of normal before injection.
Free T3 increased in two ofthese patients to high levels. However,
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Table 2 Uptake in %ID kg-' of simultaneously injected iodine-labelled E48
IgG and U36 IgG for individual patients in tumour biopsies obtained from the
surgical specimens 7-8 days after injection
Patient 1251/311-labelled E48 1311/1251-labelled U36
1 1.8 2.9
2 3.1 5.2
3 8.2 9.4
4 31.2 13.7
5 3.3 3.7
6 2.7 4.1
7 2.1 4.6
8 10.7 12.6
9 8.2 10.9
10 18.2 15.2
Figure 1 Anterior (A) and posterior (B) whole-body images of patient 3, 3
days after injection of 1311-labelled mE48 IgG. Note the visualization of the
lateral tongue carcinoma on the left side (arrow)
A B
Figure 2 Anterior (A) and posterior (B) whole-body images of patient 8, 4
days after injection of 1311-labelled mU36 IgG. Note the visualization of the
lateral tongue carcinoma on the left side (arrow)
the patients remained clinically euthyroid and FT4 and total T3
levels remained within normal limits. In those two patients the
thyroid was visualized. Further analyses will be performed to find
out whether these changes in TSH are related, for example, to the
administration of Lugol's solution, and the changes in T3 to the
administration of MAbs and experimental artifacts in the assay
systems used.
Radioimmunoscintigraphy with mMAbs E48 and U36
Whole-body images were obtained up to 3 (n = 2), 4 (n = 4), 6 (n =
2) and 8 (n = 1) days p.i. One patient did not comply with the
imaging protocol and was lost to follow-up. No selective targeting
outside the head and neck region was observed (Figures 1 and 2).
The tracer was homogeneously distributed in the area of the liver,
spleen and kidneys and, in some patients with both mMAb E48
and mMAb U36, the lungs showed faint uptake. The scrotal area
was visualized with mMAb E48 as well as with mMAb U36. The
skeleton/bone marrow was not visualized. In six out of nine
patients, the primary tumour was visualized. The quality of the
images was insufficient to detect lymph node metastases owing to
the use of a relative low dose of 1311.
Biodistribution ofmMAbs E48 and U36, 7-8 days after
injection
The activity uptake in biopsies from the surgical specimen is
shown in Tables 2 and 3. The mean uptake of iodine was the
highest in tumour tissue: 8.9 8.9 %ID kg-' for iodine-labelled
mE48 IgG and 8.2 4.4 %ID kg-' for iodine-labelled mU36 IgG.
Table 2 shows that the variability in tumour uptake is smaller for
mMAb U36 (range 2.9-15.2 %ID kg-') than for mMAb E48
(range 1.8-31.2 %ID kg-'). Moreover, it appears that in eight out
often patients the tumour uptake ofmU36 IgG was higher than the
uptake ofmE48 IgG.
High uptake of the mMAb E48 and the mMAb U36 iodine
labels was also seen in normal squamous epithelium of oral
mucosa, tongue tissue and skin. These uptake levels were lower
than in tumour tissue, but only significantly for mU36 IgG uptake
in mucosa and tongue (P < 0.01 and P < 0.02 respectively).
Tumour-positive lymph nodes contained more iodine than tumour-
negative nodes for mE48 IgG (P < 0.2, mean ratio 2.0 1.1) and
mU36 IgG (P < 0.01, mean ratio 3.0 ± 1.2). Iodine uptake in other
normal tissues was low, except for iodine-labelled mU36 IgG in
glandular tissue. Low levels of activity were seen in bone marrow
biopsies. Bone marrow aspirations showed mean iodine levels
which were similar for mE48 IgG and mU36 IgG and almost
similar to the activity levels in blood (mean bone marrow aspirate
blood ratios of 0.9 0.0 and 1.0 ± 0.1 in the case of mE48 IgG
and mU36 IgG respectively). The activity in the plasma of the
bone marrow aspirate was higher than in the cellular sediment. The
mean plasma activity in the bone marrow aspirate was slightly
lower than in blood plasma; mean bone marrow aspirate
plasma-blood plasma ratios were 0.9 ± 0.3 and 1.0 0.1 for mE48
IgG and mU36 IgG respectively.
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Table 3 Uptake of simultaneously injected iodine-labelled E48 IgG and U36 IgG in biopsies obtained from the surgical specimens 7-8 days after injection
'2511311-labelled E48 IgG (%ID kg-') '311251-labelled U36 IgG (%ID kg-')
Tissue Mean t s.d. Range Mean e s.d. Range n
Tumour 8.9 ± 8.9 1.8-31.2 8.2 ± 4.4 2.9-15.2 10
Mucosa 4.1 ± 1.4 2.0-6.8 4.0± 1.4 1.6-5.8 10
Tongue 5.8 ± 2.7 1.8,-8.8 4.4 ± 2.3 1.3-7.9 5
Skin 2.5±1.0 1.3-4.2 2.5± 1.0 1.5-4.2 5
Positive lymph node 1.3 ± 1.2 0.4-4.6 2.0 ± 1.1 0.5-4.6 9
Negative lymph node 0.6t ±0.3 0.3-1.3 0.7t ±0.4 0.3-1.4 10
Muscle 0.4 ±0.2 0.2-0.7 0.4t ±0.2 0.2-1.0 10
Fat 0.3± 0.2 0.2-0.7 0.4± 0.2 0.1-1.0 10
Submandibular gland 1.1 + 0.6 0.6-2.5 3.9 ± 1.2 2.0-5.8 10
Sublingual gland 0.2 1.4 1
Vein 0.7 ± 0.3 0.4-1.1 0.8 ± 0.3 0.3-1.4 7
Bone marrow biopsy 0.4 ± 0.2 0.2-0.7 0.5 ± 0.2 0.2-0.7 6
Total bone marrow aspiration 1.2 ± 0.4 0.7-1.7 1.5 ± 0.5 0.4-1.8 6
Supernatant bone marrow aspiration 1.7 ± 0.7 0.7-2.9 2.1 ± 0.9 0.5-3.0 6
Sediment bone marrow aspiration 0.8 ± 0.9 0.3-2.9 0.5 ± 0.2 0.2-0.7 6
Blood 1.4±0.4 0.8-1.9 1.5 ±0.6 0.3-2.7 9
Plasma 2.1 ± 0.5 1.3-2.9 2.3 ± 0.8 0.6-3.8 9
a Number of patients from whom biopsies were obtained.
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Figure 3 Primary tumour to non-tumour ratios ofsimultaneously injected iodine-labelled mE48 IgG (-) and mU36 (O) IgG in mucosa (Mc; n = 10), tongue (To;
n = 5), skin (Sk; n = 5), positive lymph node (PL; n = 9), negative lymph node (NL; n = 10), muscle (Ms; n = 10), fat (Ft; n = 10), submandibular gland (Sm; n =
10), sublingual gland (SI; n = 1), vein (Ve; n = 7), bone marrowbiopsy (BB; n = 6), total bone marrow aspiration (BA; n = 6), supernatant of bone marrow
aspiration (Su; n = 6), sediment of bone marrowaspiration (Se; n = 6), blood (BI; n = 9) and plasma (PI; n = 9)
For iodine-labelled mE48 IgG, the mean tumour to non-tumour
ratios varied between 1.8 for tongue and 34.2 for fat tissue, while
for iodine-labelled mU36 IgG these values varied between 2.1 for
sublingual gland and 28.7 for fat tissue (Figure 3). For mucosa,
tongue, skin, submandibular gland, muscle, blood and bone
marrow aspirate these ratios were 2.5, 1.8, 5.5, 9.8, 25.2, 4.7 and
4.0, respectively for mE48 IgG and 2.3, 2.3, 4.1, 2.4, 21.0, 5.8
and 5.8, respectively for mU36 IgG. Increase of MAb doses
from 11-51 mg did not alter the activity levels in tissues or the
tumour to non-tumourratios.There were no significantdifferences
in uptake values or tumour to non-tumour ratios between
mE48 IgG and mU36 IgG, except for the uptake in glandular
tissue (P <0.001).
Pharmacokinetics
The time vs radioactivity curves ofiodine-labelled mE48 IgG and
mU36IgGbest fit a two-compartmentmodel. There was no signif-
icant difference in elimination from the blood for iodine-labelled
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Figure 4 Distribution of mE48 IgG throughout tumour biopsies obtained from HNSCC patients 2 days after injection of 2 mg (A and B), 12 mg (C and D) and 52
mg (E and F). A, C and E represent MAb distribution as assessed by immunohistochemical staining with rabbit anti-mouse IgG. B, D and E represent antigen
expression (maximum MAb binding) as assessed by immunohistochemistry with mE48 IgG followed by rabbit anti-mouse IgG. Note the more homogeneous
distribution at higher dose, reaching binding to all tumour cells at 52 mg of mMAb E48
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Figure 5 Distribution of mU36 IgG throughout a tumour-infiltrated lymph node 2 days after injection of 52 mg of mU36 IgG. A represents MAb distribution as
assessed by immunohistochemical staining with rabbit anti-mouse IgG. B represents antigen expression (maximum MAb binding) as assessed by
immunohistochemistry with mU36 IgG followed by rabbit anti-mouse IgG. Note the binding of mU36 IgG to all tumour cells in this lymph node metastasis
mE48 IgG and mU36 IgG: t12a and t1/20 were 5.1 + 5.3 and 81.3 ±
81.6 hfor mE48 IgG and 6.1 ± 3.0 and 66.1 ± 29.5 hformU36IgG
respectively.
There was also no significant difference in the excretion of
iodine-labelled mE48 IgG and mU36 IgG in urine during the first
48 h: 23.0 ± 6.0 and 21.4 ± 5.1% ofthe injected dose respectively.
Bone marrow dosimetry
Red marrow residence time and whole-body residence time were
4.1 ± 1.5 h and 85.5 ± 21.5 h respectively for mE48 IgG, and4.3 ±
1.9 h and 88.5 ± 20.6 h respectively for mU36 IgG. The red
marrow dose was calculated to be 1.89 ± 0.59 rad mCi-1 for 131I-
labelled mE48 IgG and 2.00 + 0.75 for 13II-labelled mU36 IgG.
Further characteristics of E48 IgG AND U36 IgG
Distribution ofthe mMAbs E48 and U36 throughout the
tumour
Distribution ofMAbs throughout the tumourwas analysed immuno-
histochemically in tumour biopsies obtained from patients who had
been injected with either mE48 IgG or mU36 IgG alone (previous
studies). Figure 4 shows typical mE48 IgG uptake in tumourbiopsy
specimens of three patients who had received 2, 12 and 52 mg of
E48 IgG. Serial sections ofeach biopsy were incubated with rabbit
anti-mouse IgG to demonstrate in vivo tumouruptake ofmE48 IgG
(sections A, C and E), or with mMAb E48 followed by rabbit anti-
mouse IgG to demonstrate total E48 antigen expression, the
maximum mE48 IgG binding (sections B, D and F). After injection
of 2 mg, a very heterogeneous distribution of mE48 IgG was
observed. After injection of 12 mg of MAb, the distribution was
much more homogeneous, while after injection of52 mg almost all
tumour cells were targeted by mE48 IgG. A similar distribution
pattern was observed formU36 IgG as illustrated for a tumour-infil-
trated lymph node obtained from a patient who had received 52 mg
ofU36IgG (Figure5). mE48 IgG ormU36 IgG could bedetected in
all tumour biopsies of patients who had received 12 or 52 mg of
MAb; also in biopsies from tumourdeposits not detected by RIS.
ImmunogenicityofmMAbs E48and U36
To assess the immunogenicity of MAbs mE48 and mU36, serum
samples obtained from patients before and 4-8 weeks after injec-
tion ofmE48 F(ab')2 (group 1), mE48 IgG (group 2), mE48 F(ab')2
plus mE48 IgG (group 3), mU36 IgG (group 4) and mE48 IgG
plus mU36 IgG (group 5) were analysed forthe presence ofhuman
anti-mouse antibodies (HAMA) with an in-house mE48 F(ab')2-,
mE48 IgG- and/ormU36 IgG-related HAMA assay. Considering a
HAMA titre of 2 500 to be positive, preMAb infusion samples
were negative (HAMA titres < 50) for all patients (Figure 6).
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Figure 6 Individual human anti-mouse antibody (HAMA) titres before and 4-8 weeks after injection of (A) mE48 F(ab')2, (B) mE48 IgG, (C) mE48 F(ab')2 plus
mE48 IgG, (D) mU36 IgG and (E) mE48 IgG plus mU36 IgG at different MAb doses
Three out of 16 patients (19%) who had received 1 mg (n = 14) or
11 mg (n = 2) ofmE48 F(ab')2 alone showed a HAMA response as
measured in the F(ab')2 related HAMA assay. The highest titre
found was 811. Two out offive patients (40%) who had received 1
mg of mE48 IgG alone showed an anti-E48 IgG response with
titres of 1558 and 4154 respectively. Ten out of 13 patients (77%)
who received a cocktail of 1 mg of mE48 F(ab')2 and 1-51 mg of
mE48 IgG showed a HAMA response with titres up to 3709, when
measured in the E48 IgG-related HAMA assay. When the same
sera were analysed with the F(ab')2-related HAMA assay, seven
out of 13 appeared to be positive.
HAMA responses were also observed in three out of eight
patients (37%) who had received 2-52 mg of mU36 IgG. None of
the ten patients who received 11 or 51 mg of mE48 IgG and mU36
IgG simultaneously showed a HAMA response when measured in
the mE48 IgG- or mU36 IgG-related HAMA assay.
ADCC-mediating potential ofmMAbs andcMAbs E48
and U36
ADCC assays with MAbs E48 and U36 revealed that spontaneous
chromium release neverexceeded 20%, while antibody-independent
killing was less than 10%. When cMAb E48 was included in this
assay at an effector-target ratio of 100:1, specific lysis percentages
of 62%, 72% and 96% were found respectively (Figure 7). For
cMAb U36 these values were 1.2%, 5.2% and 3.5%, for mMAb E48
6%,11% and 17% and formMAbU365.4%,3.0% and4.7%. cMAb
SF-25 served as a positive control in each ADCC assay and gave
specific lysis percentages between 63% and 78% (data not shown).
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DISCUSSION
In previous clinical studies, we demonstrated a selective and high
uptake level of mE48 IgG and mU36 IgG in antigen-positive
HNSCC 2 days after injection (De Bree et al, 1995a, b). In the
present study, we show that the level of both MAbs in HNSCC
remains high 7-8 days after injection. Statistical analysis showed
no significant differences in tumour uptake of the two MAbs.
Distribution of the MAbs throughout the tumour was heteroge-
neous when 2 mg of mMAb had been injected. At a mMAb dose
of 12 mg, the distribution was much more homogeneous and at 52
mg a homogenous distribution was observed. While cE48 IgG
appeared to have a high ADCC-mediating potency, this was not
the case for mE48 IgG, mU36 IgG and c36 IgG. mU36 IgG
appeared to be less immunogenic than mE48 IgG. In previous
immunohistochemistry studies, it has been established that MAb
E48 shows a homogeneous reactivity pattern with 70% of the
HNSCC and MAb U36 with 96% ofthese tumours (De Bree et al,
1994a); all data are now available for the selection of one ofthese
MAbs for adjuvant RIT and to estimate the feasibility ofthis ther-
apeutic approach.
The most important requirement for a MAb to be used in adju-
vant RIT is thatthe MAb shouldbe capable ofselective delivery of
a sufficiently high dose of radioactivity to all tumour deposits,
including tumour nodules, malignant cell clusters and single
tumour cells. For 99mTc-labelled mMAb E48 and U36, we found
mean tumour uptake levels of 30.6 and 20.4 %ID kg-' 2 days after
injection (De Bree et al, 1995b), while 7 days after injection the
mean activity levels of iodine-labelled mMAb E48 and U36 in the
tumour were still 8.9 and 8.2 %ID kg-'.
At our laboratory, an analogous 99mTc- and 1'6Re-labelling
chemistry for MAbs directed to HNSCC has been developed,
giving the option to use 99mTc and 186Re as a 'matched pair' for
imaging, dosimetry calculations and therapy (Van Gog et al,
1996). In these studies, a similar biodistribution of 1251-, 1311-,
99mTc- and I86Re-labelled MAbs was demonstrated, and therefore it
seems reasonable to use the biodistribution values on iodine-
labelled mE48 IgG and mU36 IgG as obtained in HNSCC patients
for dosimetry predictions on '86Re-labelled mE48 IgG and mU36
IgG conjugates. Assuming that patients tolerate a dose of200 mCi
of 186Re, as was the case in a first phase I clinical trial with '86Re-
labelled NR-LU-10 IgG described by Breitz et al (1992), and
assuming an energy per transition of0.73 g.cGy ([tCi h)-1 for '86Re
(Weber et al, 1989), one may expect an absorbed tumour dose of
approximately 20 Gy. To estimate whether this will be sufficient
for obtaining cures in adjuvant therapy trials with HNSCC
patients, we recently performed RIT studies with '86Re-labelled
E48 IgG in nude mice bearing HNSCC of variable size. A single
treatment of mice bearing xenografts with a mean volume of 140
mm3 with 200-600 [tCi of 186Re-labelled mE48 IgG resulted in
18-50% complete remissions, while the absorbed tumour dose
was 11-34 Gy (Gerretsen et al, 1993). In this animal model, RIT
with 186Re-labelled mE48 IgG was more effective than RIT with
I3'l-labelled mE48 IgG. When mice with xenografts of 75 mm3
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were treated with 600 iCi of 186Re-labelled mE48 IgG, 100%
complete remissions were observed (Gerretsen et al, 1994). In
these latter tumours, the mean absorbed dose was 85 Gy. Similar
results were recently obtained with I86Re-labelled mU36 IgG in the
same animal model (data not shown). These studies indicate that
the decreased energy absorption in smaller tumours is compen-
sated by the higher tumour uptake of MAbs. Also, recent results
from clinical RIT studies using intraperitoneally administered
186Re-labelled NR-LU-10 IgG or '311-labelled MAb MOvl8 in
adjuvant therapy of ovarian cancer patients showed that RIT may
be particularly effective in eradicating minimal residual disease
(Jacobs et al, 1993, Crippa et al, 1995).
These dosimetry estimations indicate the feasibility of adjuvant
RIT with radiolabelled E48 IgG or U36 IgG in head and neck
cancer patients. However, these considerations are based on mean
tumour uptake values and assume a uniform distribution of
radioactivity throughout the tumour. It should be noted that for
mMAb U36 the tumouruptake values show alarge scatter,ranging
from 8.0-43.0 %ID kg-' 2 days after injection, and from 2.9-18.2
%ID kg-' 7 days after injection. For mMAb E48 IgG,this scatter is
even larger ranging from 7.2-82.3 %ID kg-' 2 days after injection,
and 1.8-31.2 %ID kg-' 7 days after injection. It is not yet clear
which patient and tumour characteristics influence tumour uptake
of MAbs. Buist et al (1995b) analysed several tumour characteris-
tics in ovarian cancer patients. Only antigen expression was
proved to be related to tumouruptake. In HNSCC patients, antigen
expression, tumour size and tumour site may influence tumour
uptake (R de Bree etal,manuscript inpreparation). Furthermore, it
can be stated that heterogeneous distribution of a radioimmuno-
conjugate throughout the tumour is unwanted in RIT because this
can result in overkill in certain tumour areas, while leaving other
areas relatively unaffected. In the present study, we show that the
distribution of mMAb E48 and U36 becomes more homogeneous
when a higher MAb dose is administered; a phenomenon also
observed in otherpreclinical and clinical studies (Blumenthal et al,
1991; Oosterwijk et al, 1993). With respect to this, a MAb dose of
about 50 mg is recommended for future RIT studies because this
dose resulted in homogeneous distribution throughout the tumour.
A much higher MAb dose will result in saturation of antigenic
sites, while other disadvantages are related to costs and possibly to
the immunogenicity ofthe MAb.
Although uptake of mE48 IgG and mU36 IgG was highest in
tumour tissue, 2 as well as 7 days after injection, there was also
high uptake in normal squamous epithelia, such as oral mucosa,
tongue and skin, which can be explained by the presence of
antigen in these tissues. However, it can be calculated from the
biodistribution data that the absorbed dose for large tumours will
on average be twice thatofnormal squamous epithelia. In adjuvant
therapy this difference may be larger owing to the higher MAb
uptake in small tumours. In that case anti-tumour effects can be
expected with limited toxic side-effects caused by concomitant
irradiation ofnormal squamous epithelium.
Uptake at non-tumour sites, especially the bone marrow, should
be considered, since bone marrow has been identified as the dose-
limiting organ in RIT. Data on bone marrow dosimetry indicate
that the radiation dose delivered to the bone marrow by mE48 IgG
or mU36 IgG is similar.
It may be beneficial for a MAb used for RIT to have ADCC-
mediating potential. ADCC, by helping to eradicate single dissem-
inated cells orcell aggregates, may be additive to radiation effects.
We showed that E48 IgG was highly effective in mediating ADCC
when the murine yI region was substituted for the human yl
constant region. Unfortunately, we have not been able to demon-
strate any ADCC-mediating capacity of cMAb U36. Cloning
strategies and expression vectors used for the construction of
cMAb U36 and cMAb E48 were the same. In contrast, host cells
used for transfection were different for both cMAbs. The ADCC
assay developed for evaluating cMAb E48 had to be adapted for
cMAb U36 owing to the sensitivity ofthe U36 antigen for trypsin
treatment. It is unlikely, however, that these factors are responsible
for the ineffectiveness of cMAb U36 in ADCC assays. A more
likely explanation is that the epitope recognized by MAb U36,
recently identified as being part of CD44v6, is not a favourable
target epitope for ADCC (Van Hal et al, in press). Mediation of
ADCC via the MAb Fc regions is dependent on the distance
between Fc tails, and this distance may be related to the epitopes
recognized.
In general, immunogenicity of a MAb is only a problem when
the MAb is administered repeatedly. Although uncommon,
adverse reactions like anaphylactic reactions can occur
(Riethmuller et al, 1994). Furthermore, rapid clearance of infused
MAb will occur upon subsequent administrations resulting in a
diminished targeting efficiency of the MAb to the tumour
(Khazaeli et al, 1994). In the present study, mU36 IgG appeared to
be less immunogenic than E48 IgG. Up to now just three of 18
patients receiving 1-52 mg of mU36 IgG have shown a HAMA
response when measured in the mU36 IgG-related HAMA assay,
and this frequency may fall when cU36 IgG is used in RIT studies.
In this and previous papers, we have shown biodistribution data
indicating that mE48 IgG and mU36 IgG are equally well suited
fortargeting antigen-positive tumourdeposits. Because ofits more
homogeneous reactivity pattern, however, we think that MAb U36
is more generally applicable and therefore more suitable for RIT
than MAb E48. Based on the aforementioned considerations, we
will give priority to a phase I RIT trial with 186Re-labelled cU36
IgG in head and neck cancer patients with inoperable local or
regional recurrences or distant metastases. In this radiation dose-
finding study, patients will receive a single injection of the
radioimmunoconjugate at a protein dose of 50 mg. When 186Re-
labelled cU36 IgG is well tolerated and dosimetry estimations
show the feasibility ofRIT, an adjuvant RIT trial will be started.
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